• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To NewAmsterdam Pharma (NAMS) Plunging Sales And Deepening Losses

    Simply Wall St·08/19/2026 02:29:56
    语音播报
    • In August 2026, NewAmsterdam Pharma reported second-quarter 2026 results showing sales of US$3.7 million versus US$19.15 million a year earlier, alongside a wider net loss of US$64.14 million compared with US$17.36 million.
    • Over the first half of 2026, the company’s sales fell to US$6.74 million while its net loss roughly doubled to US$112.58 million, highlighting rising costs against shrinking revenue.
    • Next, we examine how this sharp revenue drop and widening losses shape NewAmsterdam Pharma’s investment narrative and future risk profile.

    Find 50 companies with promising cash flow potential yet trading below their fair value.

    What Is NewAmsterdam Pharma's Investment Narrative?

    To own NewAmsterdam Pharma today, you have to believe that obicetrapib’s late-stage pipeline and emerging regulatory momentum, including the recent CHMP positive opinion for Ubeslo and Evlarco, will ultimately matter more than the current financial strain. The August 2026 results, with sales sliding to US$3.7 million in the quarter and losses widening sharply, put funding and execution risk more firmly in the foreground and could shorten the runway before the market demands clearer visibility on revenue from Menarini royalties or other partnerships. Near term, investors are likely to focus on upcoming EU and U.S. regulatory decisions, Phase 3 readouts and any signals on commercialization timing, and to reassess whether the company’s cash burn and management changes increase the odds of dilution or delay. Recent earnings now sit squarely at the center of that risk discussion.

    However, one key financing risk now looks harder to ignore for shareholders.

    Despite retreating, NewAmsterdam Pharma's shares might still be trading above their fair value and there could be some more downside. Discover how much.

    Exploring Other Perspectives

    NAMS 1-Year Stock Price Chart
    NAMS 1-Year Stock Price Chart

    The three Simply Wall St Community fair value views span from US$51.44 to a very large US$1,089.27, showing how far apart individual expectations sit. Set that against the recent collapse in quarterly sales and rising losses, and you can see why many readers will want to examine several contrasting risk and catalyst views before deciding how NewAmsterdam’s story fits their portfolio.

    Explore 3 other fair value estimates on NewAmsterdam Pharma - why the stock might be a potential multi-bagger!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free NewAmsterdam Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.

    Interested In Other Possibilities?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.